Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old

Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old

Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving thi...

Full description

Bibliographic Details
Main Authors: Khaled Greish, Abdulla Alawadhi, Ahmed Jaradat, Amer Almarabheh, Marwa AlMadhi, Jaleela Jawad, Basma Alsaffar, Ejlal Alalawi, Adel Alsayyad, Afaf Merza, Batool Alalawi, Donia Qayed, Ahmed Humaidan, Manaf Al Qahtani
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Vaccines
Subjects:
COVID-19
BBIBP-CorV
children 3–12 years old
the anti-spike
anti-nucleocapsid
neutralizing antibody
Online Access:https://www.mdpi.com/2076-393X/10/4/586

Internet

https://www.mdpi.com/2076-393X/10/4/586

Similar Items